ArticleCureus2025
Comparative Efficacy of Once-Weekly Somatrogon Versus Daily Growth Hormone Therapy in Children With Idiopathic Growth Hormone Deficiency: A Real-World Retrospective Study From Greece.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study.Pituitary · 2026Trial
- Weekly somatrogon vs daily somatropin: a propensity score-matched analysis of growth outcomes from clinical data vs KIGS.Journal of the Endocrine Society · 2026Article
- The efficacy and safety of weekly somatrogon treatment in turkish children with growth hormone deficiency: a real-world cohort study.Endocrine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Short stature is one of the most common reasons for referral to a pediatric endocrinologist, defined as a height of at least two standard deviations (SD) below the mean for age and sex. In this study, we aimed to compare the efficacy of daily versus weekly growth hormone (GH) treatments on the growth of children with idiopathic growth hormone deficiency (IGHD). Methods In this six-month study, participants were matched 1:1 between once-weekly somatrogon and once-daily GH treatment cohorts. A total of 20 children (aged 4-15 years) with IGHD who had never received GH treatment were included. Results Height gain at six months was 4.58 ± 1.18 cm for somatrogon-treated (weekly) subjects and 4.41 ± 0.87 cm for subjects receiving the daily regimen. Changes in height standard deviation score (SDS) by six months were similar in both treatment groups. Both treatments were well tolerated. Conclusion Both daily and weekly GH regimens significantly increased height and height SDS, with similar efficacy and safety profiles, over the six-month period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.